Form cover
Page 1 of 4

MDR/IVDR Cybersecurity Compliance Self-Assessment πŸ›‘οΈ

Cybersecurity is not optional under EU MDR and IVDR
If you’re building or maintaining medical or diagnostic devices β€” including Software as a Medical Device (SaMD) β€” your product must be secure by design and remain secure throughout its lifecycle.
This self-assessment checklist is your practical implementation guide, built from MDCG 2019-16 Rev. 1, and tailored for health-tech teams preparing for MDR/IVDR certification.
It covers the regulator’s expectations around:
- πŸ” Built-in security from the earliest design stages
- πŸ“‹ Integrated risk management across the lifecycle
- βœ… Verification and validation of security controls
- πŸ“ Comprehensive technical documentation
- πŸ‘₯ User guidance on roles and responsibilities
- πŸ”„ Ongoing maintenance (monitoring, patching, vulnerability handling)-
⚠️ Note: Some sections are iterative (e.g., Secure-by-Design + Risk Management), while others (e.g., Technical File, IFU, Maintenance) are living artefacts that must be continuously updated.
How to use this checklist
https://storage.tally.so/6db6c4e6-ffa7-435b-bb1d-5fee5437279e/Screenshot-2025-06-02-at-13.20.11.png
https://storage.tally.so/8a5881a3-41ca-42e6-ac6b-da65ad094f19/MDR-cybersecurity-checklist-steps.png

βœ… SECTION 1: Secure-by-Design

Overview: Build security into the architecture from day one; the device must stay secure on hostile networks. Design controls should eliminate or reduce risk by design and never compromise essential performance.

1.1 Do you maintain a dedicated cybersecurity requirements specification that defines security objectives (CIA), auth levels, cryptographic strength, logging needs, and update mechanisms?

A
B
C

1.2 Have you drafted system architecture and data-flow diagrams that mark trust boundaries, encryption points, identity providers, and the secure-boot chain?

A
B
C

1.3 Do you implement secure-by-default configurations, runtime least privilege, separation of safety-critical modules, and secure key storage?

A
B
C

1.4 Does your system include a cryptographically signed update mechanism with rollback capability and atomic integrity checks?

A
B
C

1.5 Have you validated safety-cybersecurity interplay β€” such as what happens if a security control interferes with clinical access or emergency functionality?

A
B
C

πŸ” SECTION 2: Security Risk Management

Overview: Extend the ISO 14971 risk file to cover cyber threats. Identify, score, mitigate and justify cyber risks within the overall benefit-risk analysis.

2.1 Have you extended your Risk Management Plan to include cybersecurity threats, roles, and acceptance criteria (e.g., β€œno unmitigated path to catastrophic harm”)?

A
B
C

2.2 Do you perform structured threat modeling that includes assets, attacker profiles, attack paths, and misuse scenarios?

A
B
C

2.3 Are risks scored using both CVSS and a clinical impact scale to reflect technical and patient safety severity?

A
B
C

2.4 Do you use layered controls (design > protective > user info) and feed gaps back into earlier design phases?

A
B
C

2.5 Are residual risks re-scored and justified in the benefit-risk analysis, with disclosures tagged for IFU (Instructions for Use)?

A
B
C

2.6 Do you maintain bidirectional traceability between the risk file and your design/testing changes?

A
B
C

🌐 SECTION 3: Minimum IT Requirements & Operating Environment

Overview: Specify only the essential external IT/network conditions. Everything else should be embedded in the product itself.

3.1 Have you listed all intended operating environments (e.g., hospital LAN, clinic PC, patient home Wi-Fi, cloud infrastructure)?

Have you evaluated each identified threat for potential impact, likelihood of exploitation, and preconditions β€” and documented the rationale behind risk scoring?
A
B
C

3.2 Have you defined minimum IT specifications such as OS version, patch level, processor/RAM, browser requirements, and time sync dependencies?

A
B
C

3.3 Have you mapped required external IT security controls (e.g., antivirus, firewall, VPN) to the specific residual risks identified in your cybersecurity risk file?

A
B
C

3.4 Have you drafted a "Minimum IT Requirements" section for your IFU or Admin Deployment Guide?

A
B
C

3.5 Do you validate the product in its lowest-spec environment and re-test after major OS/platform changes?

A
B
C

πŸ§ͺ SECTION 4: Security Verification & Validation

Overview: Demonstrate that security controls are effective β€” and uncover unknown vulnerabilities β€” through continuous, structured testing.

4.1 Do you run static code analysis (SAST) and software composition analysis (SCA) during development (CI), with full scans before release?

A
B
C

4.2 Have you created and executed a formal Security Test Plan that includes feature tests (auth, crypto, logging, update), fuzzing, dynamic scanning, and penetration testing?

A
B
C

4.3 Have you performed at least one penetration test of the integrated system using qualified testers?

A
B
C

4.4 Do you handle findings with either fixes or documented risk acceptance, and update your cybersecurity risk file accordingly?

A
B
C

4.5 Do you re-run regression tests after fixes and archive the results in your Technical Documentation?

A
B
C

πŸ“ SECTION 5: Technical Documentation (Living)

Overview: Assemble all cybersecurity artifacts in your Annex II Technical File for Notified Body review and audits.

5.1 Have you created a structured Technical File index that includes: device description, cyber design, risk management, verification & validation, labeling, and PMS/PSIRT plans?

A
B
C

5.2 Have you inserted your cybersecurity risk file, SBOM, system architecture, security test evidence, and an MDR/IVDR compliance matrix into the Technical File?

A
B
C

5.3 Do you maintain a revision log for the cybersecurity documentation, updating it after patches, security incidents, or design changes?

A
B
C

πŸ“„ SECTION 6: Instructions for Use (IFU) & User Info (Living)

Overview: Equip users with cybersecurity responsibilities, IT requirements, and clear residual-risk warnings.

6.1 Does your IFU include clear cybersecurity-related warnings and precautions (e.g. residual risks, known limitations, or misuse scenarios)?

A
B
C

6.2 Have you embedded the Minimum IT Requirements from Section 3 (e.g. OS, specs, browser, network controls) into the IFU or Admin Manual?

A
B
C

6.3 Does your documentation provide practical operational guidance (e.g., change default credentials, user management, update procedures, backup/restore, incident response contact)?

A
B
C

6.4 Do you reference the Admin Manual for deeper technical guidance (e.g., SBOM, open ports, logging behavior, hardening tips)?

A
B
C

πŸ”„ SECTION 7: Post-Market Maintenance (Living)

Overview: Operate one integrated system that monitors, triages, patches, and fulfils EU vigilance duties across the entire product lifecycle. (PMS β€’ Vigilance β€’ PSIRT β€’ Updates)

πŸ” 7.1.1 Prepare & Monitor

7.1.1 Does your PMS Plan include cyber elements (CERT feeds, SBOM monitoring, telemetry, cyber complaint fields)?

A
B
C

7.1.2 Have you published the product’s support lifetime and patch SLA (e.g. critical issues patched within 60 days)?

A
B
C

7.1.3 Is there a public vulnerability-disclosure channel (PSIRT email or web form)?

A
B
C

πŸ›‘ 7.2 Intake & Triage

7.2.1 Do you log every vulnerability or incident and score them using CVSS Γ— clinical impact?

A
B
C

7.2.2 Do you submit vigilance reports within 15 days and issue FSCA where applicable?

A
B
C

πŸ› οΈ 7.3 Remediate & Release

7.3.1 Are patches or mitigations validated and cryptographically signed before delivery?

A
B
C

7.3.2 Do you issue advisories or FSCA with risk explanations and update instructions?

A
B
C

7.3.3 Do you monitor how many customers adopt the update or patch?

A
B
C

πŸ” 7.4 Feedback & Documentation

7.4.1 Do you update the Risk Table, Technical File, IFU, and SBOM after patches or incidents?

A
B
C

7.4.2 Are cyber incident trends summarized in PSUR/PMS reports and used in future design?

A
B
C